We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Atossa Therapeutics Inc is a clinical-stage pharmaceutical company operating in us. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other brea... Atossa Therapeutics Inc is a clinical-stage pharmaceutical company operating in us. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use. Show more
SEATTLE, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), today announced its support of the U.S. Food and Drug Administration (FDA) for...
SEATTLE, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (βAtossaβ or the βCompanyβ), today announced its participation in theΒ H.C. Wainwright 26th Annual Global...
SEATTLE, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (βAtossaβ or the βCompanyβ), today announced that the United States Patent and Trademark Office (USPTO) has...
SEATTLE, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (βAtossaβ or the βCompanyβ) and Quantum Leap Healthcare Collaborativeβ’ (QLHC), today announced the first...
SEATTLE, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) today announced the appointment of Michael Parks as Vice President of Investor and Public Relations. Mr. Parks...
Presented data showing 100% disease control rate after 24-week treatment with (Z)-Endoxifen in 40mg cohort of Phase 2 EVANGELINE study at the American Association for Cancer Research (AACR) Annual...
SEATTLE, July 22, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (βAtossaβ or the βCompanyβ) today announced that the 12-patient 80mg pharmacokinetic (PK) run-in cohort of the...
SEATTLE, July 02, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (βAtossaβ or the βCompanyβ), today announced the appointment of Heather Rees as the Companyβs new Chief...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0909 | -5.90298071303 | 1.5399 | 1.55 | 1.39 | 492018 | 1.47849279 | CS |
4 | 0.069 | 5 | 1.38 | 1.55 | 1.29 | 539193 | 1.41861795 | CS |
12 | 0.379 | 35.4205607477 | 1.07 | 1.55 | 1.07 | 975366 | 1.28483223 | CS |
26 | 0.139 | 10.6106870229 | 1.31 | 2.31 | 1.02 | 1420438 | 1.51537747 | CS |
52 | 0.673 | 86.7268041237 | 0.776 | 2.31 | 0.62 | 948107 | 1.36947602 | CS |
156 | -1.911 | -56.875 | 3.36 | 3.54 | 0.5 | 1218733 | 1.57363452 | CS |
260 | -0.561 | -27.9104477612 | 2.01 | 9.8 | 0.5 | 3550067 | 3.1454563 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions